NEWS

Bukwang Pharmaceutical Co., Ltd. a novel candidate for type 2 diabetes, MLR-1023 is undergoing globa

Bukwang Pharmaceutical Co., Ltd. announced on today that global phase 2b study of MLR-1023 in both US and Korea have completed the enrollment of 50% of target patients. It is a novel anti-diabetic agent currently under co-development with Melior Pharmaceutical I Inc

Bukwang’s representative says “The phase 2b study of MLR-1023 started at the end of September 2017, and since then 196 patients, about 50% of the target number (400 patients) have been received the treatment.” And also adds “it is expected to believe that the study will be completed within this year as the development schedule is accelerated and the patient enrollment rate is faster than scheduled."

In addition, "as diabetes market is dominated by SGLT2 and DPP4, which are all considered as relative novel mechanism of action, we strongly believe that success in drug development of MLR-1023 will be able to produce significant impact as of its novelty. We expect to have a significant impact on global market with value of approximately 31 billion USD.

MLR-1023 is a new drug candidate that selectively activates Lyn kinase which is involved in insulin signaling and ultimately lowers the blood glucose level.

|    ​Korean    |

7, Sangdo-ro, Dongjak-gu, Seoul, Korea 06955   Tel : 02)8288-114   Fax : 02)8288-029   CS : 02)8288-114

Copyright © 2015 Bukwang Pharmaceutical Co., Ltd.All Rights Reserved.

  • Facebook Basic Square
  • Google+ Basic Square